IPP Bureau
Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
By IPP Bureau - September 25, 2025
Ultra-high purity surfactant for biologics and parenteral drug formulations
Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
By IPP Bureau - September 24, 2025
Relonchem receives marketing authorization for Moxonidine tablets
Shelter Pharma installs 15 KW solar power plant
By IPP Bureau - September 24, 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
By IPP Bureau - September 24, 2025
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Zydus, Pinkathon to drive awareness on breast cancer across India
By IPP Bureau - September 24, 2025
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Dr. Reddy's receives positive CHMP opinion from EMA for denosumab 'AVT03'
By IPP Bureau - September 24, 2025
Prolia is a prescription medicine used to treat osteoporosis in women
Max Hospital, Saket pioneers India’s first HDF certification program for Nephrologists
By IPP Bureau - September 24, 2025
AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
By IPP Bureau - September 24, 2025
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
By IPP Bureau - September 24, 2025
The facility has been classified as Voluntary Action Indicated
Merck & Siemens join forces to accelerate AI drug discovery and development
By IPP Bureau - September 24, 2025
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Corning, SGD Pharma opens Rs 500 crore glass tubing facility in Telangana
By IPP Bureau - September 24, 2025
Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
By IPP Bureau - September 24, 2025
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
By IPP Bureau - September 24, 2025
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine
By IPP Bureau - September 24, 2025
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
